The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus (Q34469901)

2 August 2017

0 references

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus (English)

1 reference

2 August 2017

0 references

0 references

cardiovascular disease

1 reference

2

Meigs JB

1 reference

2 August 2017

Huang ES

1

1 reference

PubMed ID

11755507

2 August 2017

Singer DE

series ordinal

3

1 reference

PubMed ID

11755507

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

American Journal of Medicine

2 August 2017

1 reference

2 August 2017

111

1 reference

2 August 2017

8

1 reference

2 August 2017

633-642

1 reference

A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Cause-specific mortality in a population-based study of diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Detection and management of lipid disorders in diabetes. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Pharmacologic therapy for type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Vascular disease and lipids in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

How far should blood pressure be reduced in diabetic hypertensive patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

An assessment of clinically useful measures of the consequences of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Why sources of heterogeneity in meta-analysis should be investigated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900978-0

10.1016/S0002-9343(01)00978-0

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11755507